**Communications Director Piece**

Herthika Sivasuntharampillai

250971647

MEDSCIEN9504

Dr. Regnault

September 20, 2024

Interdisciplinary Medical Sciences

Schulich School of Medicine and Dentistry

Western University

**Assignment Acknowledgement**

Used ChatGPT for sentence flow and used grammaly. Turnitin score 22%

**PRO Statements**

1. **Advancement in neurodegenerative research and developing new treatments**

We believe the facility will play a vital role in advancing research on neurodegenerative diseases, such as Alzheimer’s, with the potential to drive significant breakthroughs in both treatment and prevention. These debilitating diseases lead to progressive brain deterioration, affecting millions worldwide. Alzheimer’s is currently the ninth leading cause of death in Canada (Government of Canada, 2024), and by 2050, it is estimated that approximately 1.7 million Canadians will be living with the disease (Dementia numbers in Canada*)*. Conducting research on these neurodegenerative disorders is crucial for developing solutions that will safeguard the health of future generations.

1. **Increased opportunities for students, researchers, and job seekers**

The facility will be an excellent avenue in generating new jobs, boost local economic development and attract global talent and research investment to the region. It will also provide the local student, researchers, and institutions with access to advanced research tools, fostering a new generation of scientists and healthcare professionals. It would also address the brain drain issue, where Canadian researchers and students often leave for better-funded positions abroad (McGowan, 2024). This facility could serve as a critical step in providing competitive research opportunities, allowing graduate students and postdoctoral fellows to gain relevant experience without needing to move to other countries.

1. **Enhance our scientific knowledge while increasing public awareness and understanding of neurodegenerative diseases.**

This facility will aid the researcher’s work to uncover new details in neurodegenerative diseases. The knowledge gained will be shared with the public in a way that makes complex science easy to understand. Despite the fact that 26% of Canadians have a family member diagnosed with Alzheimer’s and 20% know a friend or acquaintance affected by the disease, 3% of respondents had never heard of it, and 1 in 10 knew nothing about it (Martin, 2003). This gap in public knowledge highlights the need for greater awareness of neurodegenerative diseases. The public would gain greater awareness about the causes, symptoms, and potential treatments of these conditions. In turn this will help reduce any stigma and empower individuals with their valuable health information.

**AGAINST Statements**

1. **Concerns about whether the facility can be trusted to treat animals ethically and maintain transparency in its operations**

We understand the concerns that some may have about animal welfare. This facility will strictly adhere to internationally recognized guidelines for the ethical treatment of animals, including the standards set by the Canadian Council on Animal Care (CCAC) and the 3Rs principle (Replacement, Reduction, Refinement). These principles ensure that animal testing is only employed when absolutely necessary, and we will prioritize the welfare of the animals involved in our research (*Procon.org*, 2023). The facility will undergo regular independent audits and reviews by external bodies. These audits will thoroughly assess our research practices, animal welfare standards, and overall transparency. We are committed to transparency and will provide regular updates on our research and animal care practices through publicly accessible reports and online platforms. Detailed information on how we treat animals, the steps we are taking to reduce animal testing, and the outcomes of our research will be made available to the public, ensuring that everyone can see the lengths we are going to prioritize ethical responsibility.

1. **Skepticism about whether the research conducted on animals can be effectively translated and reproduced in humans**

The facility will utilize advanced animal models that mimic human neurodegenerative diseases, while refining research techniques to enhance accuracy. The use of animal models has been instrumental in developing treatments for numerous human diseases. It will integrate non-animal methods like human cell cultures and organoids to reduce reliance on animals. Efforts will also be made to create more naturalistic environments to minimize stress and ensure reliable outcomes. All research will undergo rigorous peer review and independent oversight to ensure only high-quality studies proceed (Peplow, 2024).

1. **The facility could impact the environment in a negative way**

We understand the concerns regarding the potential environmental impact of constructing this new facility. Modern facilities can be designed to not only meet the highest standards of animal welfare and research quality but also to significantly reduce energy consumption and minimize environmental footprints. Through sustainability initiatives and advanced energy-saving strategies such as low-energy ventilation and demand-based air control, these facilities can minimize their carbon footprint and operational costs. Additionally, evidence-based designs ensure long-term environmental and economic benefits by reducing life cycle costs and meeting strict sustainability regulations. This approach will support both vital research and environmental responsibility (Cubitt & Sharp 2011).

**Government’s Position**

The government fully supports the establishment of the neurodegenerative animal research facility as a key initiative to advance critical research, which could potentially lead to significant medical breakthroughs in treating debilitating neurodegenerative diseases. The facility will boost the economy and create jobs while providing students and researchers with cutting-edge tools. It will also engage with the public and increase awareness about neurodegenerative diseases.

Recognizing the concerns about animal welfare and environmental impact will be mitigated through adherence to ethical guidelines, transparency, and sustainable, energy-efficient design. The facility will balance scientific progress with environmental responsibility, supporting research and public health

**References**

Cubitt, S., & Sharp, G. (2011). *Maintaining quality and reducing energy in research animal facilities*. Animal Technology and Welfare. https://www.aircuity.com/wp-content/uploads/Maintaining-quality-and-reducing-energy-in-research-animal-facilities\_2012129724239043437500.pdf

*Dementia numbers in Canada*. Alzheimer Society of Canada. (n.d.). https://alzheimer.ca/en/about-dementia/what-dementia/dementia-numbers-canada

Government of Canada, S. C. (2024, January 15). *Alzheimer’s Awareness Month*. https://www.statcan.gc.ca/o1/en/plus/5374-alzheimers-awareness-month

Martin, S. (2003, April 15). *Canadians’ awareness of alzheimer’s disease lacking*. CMAJ : Canadian Medical Association journal = journal de l’Association medicale canadienne. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC152713/

McGowan, S. (2024, March 20). *Why Canada is losing the next generation of researchers*. University Affairs. https://universityaffairs.ca/features/feature-article/why-canada-is-losing-the-next-generation-of-researchers/

Peplow, P. V. (2024, February 5). *Animal models in medical translation: The Grand Challenge of developing new treatments for human diseases*. Frontiers. https://www.frontiersin.org/journals/medical-technology/articles/10.3389/fmedt.2024.1367521/full

Procon.org. Animal Testing. (2023, May 10). https://animal-testing.procon.org/#:~:text=Animal%20testing%20contributes%20to%20life,the%20California%20Biomedical%20Research%20Association